The utilization and challenges of Japan's MID‐NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies
- 3 April 2019
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (5) , 601-608
Abstract
Purpose: To examine the potential role of Medical Information Database Network (MID‐NET®), a newly established Japanese medical information database network, in postmarketing drug safety assessments through the characterization of its advantages and limitations in five pilot studies.Methods: The pilot studies were designed to address three major objectives in postmarketing drug safety assessments, ie, the examination of actual drug utilization, the impact of safety‐related regulatory actions, and drug‐associated risks. The five studies were conducted on the following topics: (a) utilization of codeine‐containing products and its relationship with respiratory depression, (b) impact of a Dear Healthcare Professional letter on hypocalcemia incidence associated with denosumab (Ranmark®) use, (c) risk of acute myocardial infarction associated with antidiabetic drug use, (d) risk of glucose metabolism disorders associated with atypical antipsychotic drug use, and (e) prospective monitoring of abnormal laboratory test results during new drug prescriptions.Results: The pilot studies were successfully conducted and demonstrated the value of MID‐NET® in postmarketing drug safety assessments. In particular, the ability to utilize laboratory test results as objective clinical indicators is a major advantage of this database. Potential limitations include a relatively small sample size and a lack of patient‐level data linkages among hospitals.Conclusions: MID‐NET® was confirmed to be a valuable database for postmarketing drug safety assessments. The use of laboratory test results to define clinical outcomes may allow more objective and accurate analyses to be conducted. These studies furthered our understanding of the characteristics of MID‐NET®, including its advantages and limitations.Keywords
This publication has 18 references indexed in Scilit:
- Establishment of the MID‐NET® medical information database network as a reliable and valuable database for drug safety assessments in JapanPharmacoepidemiology and Drug Safety, 2019
- Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic toolsPharmacoepidemiology and Drug Safety, 2018
- Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)Pharmacoepidemiology and Drug Safety, 2018
- Real-World Evidence — What Is It and What Can It Tell Us?New England Journal of Medicine, 2016
- The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of JapanPharmacoepidemiology and Drug Safety, 2016
- The FDA's sentinel initiative—A comprehensive approach to medical product surveillanceClinical Pharmacology & Therapeutics, 2015
- The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safetyClinical Journal of Gastroenterology, 2014
- Electronic clinical laboratory test results data tables: lessons from Mini‐SentinelPharmacoepidemiology and Drug Safety, 2014
- The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safetyPharmacoepidemiology and Drug Safety, 2012
- European Medicines Agency review of post‐authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and PharmacovigilancePharmacoepidemiology and Drug Safety, 2011